MAPK3 and prostate cancer: The results of the present study showed significantly higher fluorescence intensity of miRNAs 106a‐5p and 375‐3p, and lower immunoreactivity and the expression of genes encoding ERK1/2, p38, β‐catenin and E‐cadherin in prostate cancer compared to BPH.